Stock Events

Stock Events

Enzymatica 

€0.142500
0
+€0.00+2.52% 15:32 Today

Statistics

Day High
0.1525
Day Low
0.139
52W High
0.309
52W Low
0.126
Volume
-
Avg. Volume
-
Mkt Cap
34.59M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2025
Q2 2026
Next
-0
0.33
0.66
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-96.12%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.93MRevenue
-4.74MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap105.71B
GlaxoSmithKline, a large pharmaceutical company, competes in the production of various healthcare products, including those for respiratory diseases, potentially overlapping with Enzymatica's cold prevention products.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson offers a broad range of health products, including treatments for respiratory conditions, directly competing with Enzymatica's cold remedies.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is involved in the development and manufacturing of healthcare products, including those for respiratory health, competing with Enzymatica's enzyme-based treatments.
Novartis
NVS
Mkt Cap293.94B
Novartis produces healthcare products that address a myriad of conditions, including respiratory diseases, which places them in competition with Enzymatica.
Abbott Laboratories
ABT
Mkt Cap163.61B
Abbott Laboratories manufactures medical devices and healthcare products that can compete with Enzymatica's offerings in the general health and wellness sector.
Merck
MRK
Mkt Cap305.12B
Merck & Co., known for its wide range of pharmaceutical products, competes in the area of respiratory health treatments, relevant to Enzymatica's market.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG engages in the pharmaceutical and diagnostics business, including areas that overlap with Enzymatica's focus on respiratory and immune health.
Sanofi
SNY
Mkt Cap104.13B
Sanofi operates globally in pharmaceuticals, including treatments for respiratory conditions, competing with Enzymatica's product range.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca specializes in several major health areas, including respiratory diseases, making it a competitor to Enzymatica's enzyme-based health products.

About

Enzymatica AB (publ), a life science company, develops and sells medical devices for infectious diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care under Penzyme technology. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
Show more...
CEO
Country
Germany
ISIN
SE0003943620

Listings

STU
DE
EN9.STU
MU
DE
EN9.MU
ST
SE
ENZY.ST
F
DE
EN9.F

0 Comments

Share your thoughts

FAQ

What is Enzymatica stock price today?▼
The current price of EN9.STU is €0.14 EUR — it has increased by +2.52% in the past 24 hours. Watch Enzymatica stock price performance more closely on the chart.
What is Enzymatica stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Enzymatica stocks are traded under the ticker EN9.STU.
Is Enzymatica stock price growing?▼
EN9.STU stock has risen by +3.64% compared to the previous week, the month change is a -21.7% fall, over the last year Enzymatica has showed a -36.95% decrease.
What is Enzymatica market cap?▼
Today Enzymatica has the market capitalization of 34.59M
When is the next Enzymatica earnings date?▼
Enzymatica is going to release the next earnings report on October 29, 2026.
What is Enzymatica revenue for the last year?▼
Enzymatica revenue for the last year amounts to 4.93M EUR.
What is Enzymatica net income for the last year?▼
EN9.STU net income for the last year is -4.74M EUR.
In which sector is Enzymatica located?▼
Enzymatica operates in the Materials sector.
When did Enzymatica complete a stock split?▼
Enzymatica has not had any recent stock splits.